Skip to main content
52°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Arcutis Biotherapeutics, Inc.
< Previous
1
2
Next >
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
March 07, 2025
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting
February 28, 2025
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
February 26, 2025
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
February 25, 2025
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology
February 24, 2025
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million
January 12, 2025
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
December 16, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
November 13, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update
November 06, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting
October 24, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
October 18, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
September 25, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
September 24, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
September 19, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255
September 05, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
August 28, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
July 29, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
July 29, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
July 23, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
July 22, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
July 09, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis
July 09, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
June 10, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
June 05, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology
May 13, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
April 29, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Appoints David Topper as Chief Financial Officer
April 10, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.